Jobs
-
According to Alexza Pharmaceuticals, a Phase 2a study of AZ-002 Staccato alprazolam for the treatment of epilepsy patients with acute repetitive seizures has been initiated. The study will take place in-clinic, though AZ-002 is being… Read more . . .
-
Lupin Pharmaceuticals Coral Springs, FL R&D Center. Lupin Pharmaceuticals. is a specialty pharmaceutical company marketing generic and branded pharmaceutical products as well as Active Pharmaceutical Ingredients (APIs). Essential Duties and Responsibilities • Conduct standard and… Read more . . .
-
Boehringer Ingelheim has announced that the Spiriva Respimat tiotropium soft mist inhaler is now available in the United States. Patients will also still be able to purchase Spiriva Handihaler, the company said. The FDA approved… Read more . . .
-
According to Nexus6, a study conducted in New Zealand has shown that 84% of children using the Smartinhaler SmartTrack device, which provides both audio and visual reminders, used their inhalers as prescribed compared to 30%… Read more . . .
-
Inhalation Asia has announced that nicotine delivery, smoking cessation, and the treatment of tuberculosis will be among the topics addressed at IA15, to be held this September in Shenyang, China. Plenary speakers for the meeting… Read more . . .
-
NovaBiotics, which has plans to develop an inhaled version of its Lynovex cysteamine (NM001) for the treatment of cystic fibrosis, has announced that it has raised £5 million in a private placement from Woodford Investment… Read more . . .
-
Aradigm Corporation announced that it has received patents for its Pulmaquin inhaled ciprofloxacin from the European and Australian patent offices. The European patent (EU Patent No. 2,079,443) is titled “Dual Action, Inhaled Formulations Providing Both… Read more . . .
-
According to MannKind Corporation, Hakan Edstrom has taken over as CEO after company founder Alfred Mann stepped down from that position effective January 9, 2015. Mann will become the Executive Chairman and “intends to remain… Read more . . .
-
According to Verona Pharma a Phase 1/2 trial of its RPL554 inhaled PDE3/4 inhibitor for the treatment of COPD has gotten underway with dosing of the first subjects. Plans are for recruitment of up to… Read more . . .
-
Hovione has announced the promotion of Filipe Gaspar to VP of R&D, reporting to CEO Guy Villax. Gaspar joined Hovione in 2003 and has held a number of positions at the company, including Director of… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden